Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
163 hedge funds and large institutions have $96.6M invested in Esperion Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 36 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.87% less ownership
Funds ownership: 57.41% → 49.55% (-7.9%)
12% less funds holding
Funds holding: 186 → 163 (-23)
44% less capital invested
Capital invested by funds: $171M → $96.6M (-$74.9M)
61% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 36
68% less call options, than puts
Call options by funds: $242K | Put options by funds: $768K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
+$4.68M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
+$3.03M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.68M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.16M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$868K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$14M |
| 2 |
Morgan Stanley
New York
|
-$5.54M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$2.67M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.54M |
| 5 |
JP Morgan Chase
New York
|
-$1.36M |
ESPR Hedge Fund Activity: Q2 2025 in Review
163 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2025, worth a combined $96.6M — down 44% from $171M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ESPR and 14 opened new positions — a net loss of 22 holders — while 39 trimmed existing stakes and 57 added.
The largest buyer was PenderFund Capital Management, adding an estimated $4.68M. The largest seller was Bellevue Group, exiting entirely with an estimated $14M sold.
- 163 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2025, down from 186 in Q1 2025.
- Funds reported $96.6M of Esperion Therapeutics stock for Q2 2025, down 44% quarter-over-quarter.
- 14 funds opened new Esperion Therapeutics positions in Q2 2025 and 36 closed out, a net change of -22 holders.
- The largest Esperion Therapeutics buyer in Q2 2025 was PenderFund Capital Management, an estimated $4.68M added.
- The largest Esperion Therapeutics seller in Q2 2025 was Bellevue Group, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2025.